Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab
about
Applications of 211At and 223Ra in targeted alpha-particle radiotherapyAn overview of targeted alpha therapy.Radioimmunotherapy with α-particle-emitting radionuclides.Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.Cancer radioimmunotherapy.Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapyUnconventional nuclides for radiopharmaceuticalsRadioimmunotherapy of solid tumors: searching for the right target.Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.Response of meningeal carcinomatosis from breast cancer to capecitabine monotherapy: a case report.Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.
P2860
Q24610016-D730BA23-20C9-4FDB-9A20-B4ED8F4D4AE2Q34238513-659D4E33-F1A7-44D2-B089-559A1B7CD898Q34419562-6795DD26-3334-4135-A8B3-9EC61A540DC1Q34555716-3002BC7B-12AE-4529-90EC-4365C7619D98Q35070045-13EB8A0D-3477-47A0-9AA4-3480E59A5746Q35650472-05B0E7CA-E288-4197-90F5-540651A5C048Q36534262-28382777-8FB2-4A2E-A4E1-410375985C64Q37129181-F68DDEF0-6199-4D9B-9AE2-88D2370FF3D0Q37804904-6B2A5F7F-AF05-4386-8552-C62AF28CEE0BQ38054112-88803F48-FC2F-4297-8A01-90B5DCF6E973Q38663041-73413D07-B4D6-4815-9366-C10984AE1E8EQ41865540-6F127D9A-B7B8-4CC7-9944-C99AA1701538Q43246535-6BAA4C13-AF90-4108-A25F-4F5A40686E3AQ50068024-AFDD924B-1692-48F4-9786-70371EAD5D43Q55042518-3F87AEF5-9625-4DF1-88AD-A660018C6E89
P2860
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of HER2-positive bre ...... ng (211)At-labeled trastuzumab
@en
Treatment of HER2-positive bre ...... ion of alpha-particle-emitting
@nl
type
label
Treatment of HER2-positive bre ...... ng (211)At-labeled trastuzumab
@en
Treatment of HER2-positive bre ...... ion of alpha-particle-emitting
@nl
prefLabel
Treatment of HER2-positive bre ...... ng (211)At-labeled trastuzumab
@en
Treatment of HER2-positive bre ...... ion of alpha-particle-emitting
@nl
P2093
P2860
P1476
Treatment of HER2-positive bre ...... ng (211)At-labeled trastuzumab
@en
P2093
Abraham Boskovitz
John H Sampson
Michael R Zalutsky
Tatsunori Okamura
P2860
P304
P356
10.1016/J.NUCMEDBIO.2009.04.003
P577
2009-08-01T00:00:00Z